Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol

Marie-Eve Muller, Menno Pruijm, Olivier Bonny, Michel Burnier, Anne Zanchi, Marie-Eve Muller, Menno Pruijm, Olivier Bonny, Michel Burnier, Anne Zanchi

Abstract

Introduction: Empagliflozin is an SGLT-2 inhibitor (SGLT-2i) which belongs to a new class of hypoglycemic drugs with the unique property of decreasing blood glucose independently from insulin, through an increase in glycosuria. In addition to decreasing cardiovascular morbidity and mortality, empagliflozin has nephroprotective properties in high cardiovascular risk patients with type 2 diabetes. Decreased hyperfiltration and shifting towards more favorable renal fuel energetics with improved renal oxygenation may explain some of these properties. With this study, we propose to explore the effects of empagliflozin on renal tissue oxygenation using blood oxygenation level-dependent magnetic resonance imaging (BOLD-MRI).

Methods: This is a double-blind, randomized, placebo-controlled study examining the acute and chronic renal effects of empagliflozin 10 mg. The primary outcome is the effects of empagliflozin on renal tissue oxygenation as measured by BOLD-MRI. The secondary outcomes include the effects of empagliflozin on tubular function, 24 h blood pressure control, and the influence of body mass index (BMI) on the renal response to empagliflozin. Fifteen normal weight, 15 overweight, and 15 obese non-diabetic subjects (men and women) will be recruited. Each participant will undergo 24 h urine collections and blood pressure measurements on day - 1, followed by an investigation day at the study center with blood and urine sampling and renal BOLD-MRI measurements before and 180 min after the administration of 10 mg empagliflozin or placebo. This sequence of measurements will be repeated after 1 month of a daily empagliflozin or placebo intake. To investigate renal oxygenation, the renal cortical and medullary R2*, as a marker of oxygenation, will be assessed by BOLD-MRI under standardized hydration conditions: the higher R2*, the lower oxygenation.

Conclusion: SGLT-2 inhibitors have a profound effect on renal physiology. This is an important study that will explore for the first time whether inhibiting SGLT-2 with empagliflozin in healthy volunteers affects renal tissue oxygenation as determined by BOLD-MRI.

Funding: Boehringer Ingelheim Pharma GmbH & Co.

Trial registration: ClinicalTrials.gov identifier, NCT03093103.

Keywords: BOLD-MRI; Empagliflozin; Endocrinology; SGLT-2.

Figures

Fig. 1
Fig. 1
Flowchart of the study

References

    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720.
    1. Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):1801–1802.
    1. van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017;12(4):700–710. doi: 10.2215/CJN.06080616.
    1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–1462. doi: 10.1056/NEJM199311113292004.
    1. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi: 10.1056/NEJMoa011161.
    1. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860. doi: 10.1056/NEJMoa011303.
    1. ADA Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4–S5.
    1. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J. 2016;37(29):2315–2381. doi: 10.1093/eurheartj/ehw106.
    1. DeFronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36(10):3169–3176. doi: 10.2337/dc13-0387.
    1. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy. 2013;33(9):984–999. doi: 10.1002/phar.1303.
    1. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597. doi: 10.1161/CIRCULATIONAHA.113.005081.
    1. Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci. 2003;18:169–174.
    1. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–S171. doi: 10.2337/dcS15-3006.
    1. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–1122. doi: 10.2337/dc16-0542.
    1. Brezis M, Rosen S. Hypoxia of the renal medulla—its implications for disease. N Engl J Med. 1995;332(10):647–655. doi: 10.1056/NEJM199503093321006.
    1. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med. 1996;334(22):1448–1460. doi: 10.1056/NEJM199605303342207.
    1. Yin WJ, Liu F, Li XM, et al. Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. Eur J Radiol. 2012;81(7):1426–1431. doi: 10.1016/j.ejrad.2011.03.045.
    1. Prasad PV. Evaluation of intra-renal oxygenation by BOLD MRI. Nephron Clin Pract. 2006;103(2):c58–c65. doi: 10.1159/000090610.
    1. Pruijm M, Hofmann L, Piskunowicz M, et al. Determinants of renal tissue oxygenation as measured with BOLD-MRI in chronic kidney disease and hypertension in humans. PLoS One. 2014;9(4):e95895. doi: 10.1371/journal.pone.0095895.
    1. Pruijm M, Hofmann L, Maillard M, et al. Effect of sodium loading/depletion on renal oxygenation in young normotensive and hypertensive men. Hypertension. 2010;55(5):1116–1122. doi: 10.1161/HYPERTENSIONAHA.109.149682.
    1. Pruijm M, Hofmann L, Charollais-Thoenig J, et al. Effect of dark chocolate on renal tissue oxygenation as measured by BOLD-MRI in healthy volunteers. Clin Nephrol. 2013;80(3):211–217. doi: 10.5414/CN107897.
    1. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–1693. doi: 10.2337/dc15-0843.
    1. Zanchi A, Maillard M, Jornayvaz FR, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Diabetologia. 2010;53(8):1568–1575. doi: 10.1007/s00125-010-1756-2.
    1. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004;89(3):1140–1145. doi: 10.1210/jc.2003-031526.
    1. Pruijm M, Ponte B, Ackermann D, et al. Heritability, determinants and reference values of renal length: a family-based population study. Eur Radiol. 2013;23(10):2899–2905. doi: 10.1007/s00330-013-2900-4.
    1. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4(2):331–345. doi: 10.1007/s13300-013-0030-2.
    1. Milani B, Ansaloni A, Sousa-Guimaraes S, et al. Reduction of cortical oxygenation in chronic kidney disease: evidence obtained with a new analysis method of blood oxygenation level-dependent magnetic resonance imaging. Nephrol Dial Transplant. 2017;32(12):2097–105.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren